Keros Therapeutics (KROS) Operating Margin (2019 - 2025)
Keros Therapeutics posted quarterly Operating Margin of 5072.79% for Q4 2025, down 1555586.0% year-on-year from N/an in Q4 2024, and down 4602.82% on a QoQ basis from 107.87% in Q3 2025.
Keros Therapeutics (KROS) has 6 years of Operating Margin data on file, last reported at 5072.79% in Q4 2025.
- For the quarter ending Q4 2025, Operating Margin fell 1555586.0% year-over-year to 5072.79%; the trailing twelve-month figure through Dec 2025 stood at 27.66% (down 17566650.0% YoY), and the FY2025 full-year result was 27.69%, changed N/A from the prior year.
- Operating Margin for Q4 2025 stood at 5072.79%, down from 107.87% in the prior quarter.
- Across five years, Operating Margin topped out at 10483.07% in Q4 2024 and bottomed at 541000.0% in Q3 2023.
- The 5-year median for Operating Margin is 219.16% (2025), against an average of 54468.25%.
- The widest annual swing landed in 2024, when Operating Margin jumped 52588222 bps; it then slumped 1555586 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 27.18% in 2021, then tumbled by 393 bps to 134.03% in 2022, then tumbled by 24137 bps to 32486.01% in 2023, then surged by 132 bps to 10483.07% in 2024, then tumbled by 148 bps to 5072.79% in 2025.
- The last three Operating Margin figures came in at 5072.79% (Q4 2025), 107.87% (Q3 2025), and 219.16% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -5,072.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5,072.79% |
| Sep 30, 2025 | -107.87% |
| Jun 30, 2025 | -219.16% |
| Mar 31, 2025 | 71.97% |
| Dec 31, 2024 | 10,483.07% |
| Sep 30, 2024 | -15,117.78% |
| Dec 31, 2023 | -32,486.01% |
| Sep 30, 2023 | -541,000.00% |
| Mar 31, 2022 | -134.03% |
| Dec 31, 2021 | -27.18% |
| Jun 30, 2021 | -15,541.00% |
| Dec 31, 2019 | -109.12% |
| Sep 30, 2019 | -93.04% |
| Jun 30, 2019 | -106.04% |
| Mar 31, 2019 | -114.32% |